Review summary
Teaching objective: Type 2 diabetes and hypertension in a 64-year-old Black man, a former professional heavyweight boxer who runs a gym, managed under the ADA Standards of Care 2008, the 2007 AHA/ACC blood pressure guideline and the CMID monographs: A1c, kidney function by the race-free CKD-EPI 2003 equation and urine albumin, lipids and a high-intensity statin, a GLP-1 receptor agonist with cardiovascular and kidney benefit, blood pressure to below 130/80 with home readings, eye and foot examinations, and cost and access. The yearly liver check finds a high FIB-4, and the AASLD 2005 MASLD guidance leads to elastography and a diagnosis of compensated cirrhosis from MASLD; under the AASLD 2005 hepatocellular carcinoma guidance he begins ultrasound with AFP every six months, the kind of surveillance that can find liver cancer early, with variceal screening, vaccines and no alcohol. Brain health in a former boxer is addressed with a documented cognitive screen and risk-factor care, and without a diagnosis of chronic traumatic encephalopathy, which can be made only after death.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| January 12, 1944 | Born in Beaufort County, South Carolina. | CLM-0001 |
| late 1950s | Moved to Philadelphia as a teenager; worked in a slaughterhouse. | CLM-0002 |
| 1964 | Olympic heavyweight gold medal in Tokyo, with a broken left thumb; a cataract found in his left eye later that year. | CLM-0003, CLM-0004 |
| February 16, 1970 | Became undisputed heavyweight champion. | CLM-0005 |
| 1975 | Third fight of his rivalry, stopped before the fifteenth round when he could not see; vision 20/400 in the left eye. | CLM-0004, CLM-0006 |
| 1976 | Retired from boxing (one further bout in 1981). | CLM-0005 |
| 1996 | Published his autobiography, Smokin' Joe. | CLM-0011 |
| early 2000s | Living in Philadelphia and running his gym; diabetes and high blood pressure reported publicly. | CLM-0007, CLM-0008 |
| October 2011 | Diagnosed with liver cancer; hospice care at home in his last week. | CLM-0009 |
| November 7, 2011 | Died in Philadelphia at 67. | CLM-0010 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Joe Frazier was born on January 12, 1944, in Beaufort County, South Carolina, the eleventh child of a sharecropping family. | confirmed | Sielski M. Joe Frazier biography (ESPN Classic) supports Boxing legend Joe Frazier dies supports Gelston D, Dahlberg T. Philadelphia boxing legend Joe Frazier dies (Associated Press) supports Cancer catches Joe Frazier supports HISTMED Master Roster v3 context |
| D | As a teenager he moved to Philadelphia, where he had relatives, and worked in a slaughterhouse, where he punched sides of beef in the cold room. Anchors his Philadelphia home and working life in the modern social history. |
confirmed | Sielski M. Joe Frazier biography (ESPN Classic) supports |
| D | He won the heavyweight gold medal at the 1964 Olympic Games in Tokyo, fighting the final with a broken left thumb. | confirmed | Sielski M. Joe Frazier biography (ESPN Classic) supports Gelston D, Dahlberg T. Philadelphia boxing legend Joe Frazier dies (Associated Press) supports Boxing legend Joe Frazier dies supports Cancer catches Joe Frazier supports |
| D | Later in 1964 he learned that he had a cataract in his left eye; visually impaired, he turned professional anyway. The cataract grew worse, and by 1975, according to his eye doctor, his vision was 20/50 in the right eye and 20/400 in the left. Reported during his life. Anchors the reduced vision in the left eye in the modern episode. Later accounts that he hid the eye from examiners appeared only after his death and are not used. |
confirmed | Sielski M. Joe Frazier biography (ESPN Classic) supports Diskin B. Smokin' Joe had vicious left hook (ESPN Classic) supports |
| D | He became undisputed world heavyweight champion in February 1970 and held the title until January 1973, defending it four times; he retired in 1976 after a professional record of 32 wins, 4 losses and 1 draw, with 27 knockouts, and returned for a single bout in 1981. Anchors a long professional career with many blows to the head, the basis for brain-health care in the modern episode. |
confirmed | Sielski M. Joe Frazier biography (ESPN Classic) supports Joe Frazier dead at 67 (Associated Press) supports Gelston D, Dahlberg T. Philadelphia boxing legend Joe Frazier dies (Associated Press) supports |
| D | His three-fight rivalry in the 1970s included a 1971 victory that handed his opponent his first professional defeat; in the third fight, in Manila in 1975, he could no longer see, and his trainer would not let him come out for the fifteenth round. History only; the opponent is not named in this record. |
confirmed | Gelston D, Dahlberg T. Philadelphia boxing legend Joe Frazier dies (Associated Press) supports Sielski M. Joe Frazier biography (ESPN Classic) supports Joe Frazier dead at 67 (Associated Press) supports |
| D | In later life he lived in Philadelphia, where he owned and ran a boxing gym, and he had financial trouble. Anchors his work at the gym and cost concerns in the modern social history. |
confirmed | Sielski M. Joe Frazier biography (ESPN Classic) supports Gelston D, Dahlberg T. Philadelphia boxing legend Joe Frazier dies (Associated Press) supports |
| D | During his life it was reported publicly that he had diabetes and high blood pressure. The anchor for the modern diabetes and hypertension; the duration, severity and treatment in the modern episode are synthetic. |
confirmed | Sielski M. Joe Frazier biography (ESPN Classic) supports |
| D | In October 2011 he was diagnosed with liver cancer; he was in and out of the hospital from early October and received hospice care at home in his last week. History after the modern episode, as his manager and a family friend stated publicly. The modern episode contains no liver cancer; its teaching point is surveillance that can find liver cancer early. |
confirmed | Joe Frazier dead at 67 (Associated Press) supports Ex-champ Frazier dies of liver cancer (Associated Press) supports Cancer catches Joe Frazier supports |
| D | He died on November 7, 2011, in Philadelphia, at 67, after a brief illness with liver cancer. History only, recorded in one plain sentence. |
confirmed | Joe Frazier dead at 67 (Associated Press) supports Boxing legend Joe Frazier dies supports Gelston D, Dahlberg T. Philadelphia boxing legend Joe Frazier dies (Associated Press) supports |
| D | He published an autobiography, Smokin' Joe, in 1996. His nickname, used here as an alias. |
confirmed | Sielski M. Joe Frazier biography (ESPN Classic) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes | active | confirmed | both_with_link | CLM-0008 |
| S | Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure | active | confirmed | both_with_link | CLM-0008 |
| S | Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated | resolved | confirmed | active | |
| S | Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcohol | active | confirmed | active | |
| S | Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh A | active | confirmed | active | |
| S | Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin | active | confirmed | active | |
| S | Obesity, class 1 (BMI 31.4) | active | confirmed | active | |
| S | Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30 | active | confirmed | active | CLM-0004 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2008-02-16 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.4% (high) Reference Below 5.7% is normal; goal below 7% for him |
http://loinc.org · 4548-4 |
| S | 2008-02-16 | Glucose [Mass/volume] in Serum or Plasma | 168 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2008-02-16 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2008-02-16 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2008-02-16 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2008-02-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2003)/1.73 sq M | 77 mL/min/1.73 m² Reference 60 or higher without kidney damage markers is not CKD |
http://loinc.org · 98979-8 |
| S | 2008-02-16 | Albumin/Creatinine [Mass Ratio] in Urine | 18 mg/g Reference Below 30 mg/g is normal (A1) |
http://loinc.org · 9318-7 |
| S | 2008-02-16 | Cholesterol [Mass/volume] in Serum or Plasma | 212 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2008-02-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 mg/dL (high) Reference Goal below 70 mg/dL with diabetes and other risk factors |
http://loinc.org · 13457-7 |
| S | 2008-02-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 mg/dL (low) Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2008-02-16 | Triglyceride [Mass/volume] in Serum or Plasma | 210 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2008-02-16 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2008-02-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 42 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2008-02-16 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2008-02-16 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2008-02-16 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2008-02-16 | Hemoglobin [Mass/volume] in Blood | 14.2 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 2008-02-16 | Platelets [#/volume] in Blood by Automated count | 138 10*3/uL (low) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2008-02-16 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 340 pg/mL Reference 232-1245 pg/mL |
http://loinc.org · 2132-9 |
| S | 2008-02-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2008-02-16 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
| S | 2008-03-02 | Liver stiffness by US.transient elastography | 17.6 kPa (high) Reference Below 8 kPa makes advanced fibrosis unlikely; 15 kPa or higher is consistent with compensated advanced chronic liver disease |
http://loinc.org · 77615-3 |
| S | 2008-03-02 | INR in Platelet poor plasma by Coagulation assay | 1.1 Reference 0.8-1.2 |
http://loinc.org · 6301-6 |
| S | 2008-03-02 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 4.2 ng/mL Reference <=8.3 ng/mL |
http://loinc.org · 1834-1 |
| S | 2008-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2008-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2008-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2003)/1.73 sq M | 75 mL/min/1.73 m² Reference 60 or higher without kidney damage markers is not CKD |
http://loinc.org · 98979-8 |
| S | 2008-04-13 | Cholesterol [Mass/volume] in Serum or Plasma | 148 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2008-04-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 mg/dL Reference Goal below 70 mg/dL with diabetes and other risk factors |
http://loinc.org · 13457-7 |
| S | 2008-04-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 40 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2008-04-13 | Triglyceride [Mass/volume] in Serum or Plasma | 168 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2008-04-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2008-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 40 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2008-05-18 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.3% (high) Reference Below 5.7% is normal; goal below 7% for him |
http://loinc.org · 4548-4 |
| S | 2008-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2008-07-13 | Total score [MoCA] | 26 | http://loinc.org · 72172-0 |
| S | 2008-09-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.8% (high) Reference Below 5.7% is normal; goal below 7% for him |
http://loinc.org · 4548-4 |
| S | 2008-09-14 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2008-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2008-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.06 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2008-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2003)/1.73 sq M | 78 mL/min/1.73 m² Reference 60 or higher without kidney damage markers is not CKD |
http://loinc.org · 98979-8 |
| S | 2008-09-14 | Albumin/Creatinine [Mass Ratio] in Urine | 14 mg/g Reference Below 30 mg/g is normal (A1) |
http://loinc.org · 9318-7 |
| S | 2008-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2008-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2008-09-14 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2008-09-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2008-09-14 | Platelets [#/volume] in Blood by Automated count | 140 10*3/uL (low) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2008-09-14 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 4 ng/mL Reference <=8.3 ng/mL |
http://loinc.org · 1834-1 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2008-02-16 | Body height | 182 cm | 8302-2 | S |
| 2008-02-16 | Body weight | 104 kg | 29463-7 | S |
| 2008-02-16 | Body mass index (BMI) [Ratio] | 31.4 kg/m2 | 39156-5 | S |
| 2008-02-16 | Systolic blood pressure | 152 mm[Hg] | 8480-6 | S |
| 2008-02-16 | Diastolic blood pressure | 92 mm[Hg] | 8462-4 | S |
| 2008-02-16 | Heart rate | 76 /min | 8867-4 | S |
| 2008-02-16 | Respiratory rate | 16 /min | 9279-1 | S |
| 2008-02-16 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2008-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2008-03-02 | Body height | 182 cm | 8302-2 | S |
| 2008-03-02 | Body weight | 103.6 kg | 29463-7 | S |
| 2008-03-02 | Body mass index (BMI) [Ratio] | 31.3 kg/m2 | 39156-5 | S |
| 2008-03-02 | Systolic blood pressure | 148 mm[Hg] | 8480-6 | S |
| 2008-03-02 | Diastolic blood pressure | 90 mm[Hg] | 8462-4 | S |
| 2008-03-02 | Heart rate | 74 /min | 8867-4 | S |
| 2008-03-02 | Respiratory rate | 16 /min | 9279-1 | S |
| 2008-03-02 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2008-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2008-04-13 | Body height | 182 cm | 8302-2 | S |
| 2008-04-13 | Body weight | 101.8 kg | 29463-7 | S |
| 2008-04-13 | Body mass index (BMI) [Ratio] | 30.7 kg/m2 | 39156-5 | S |
| 2008-04-13 | Systolic blood pressure | 134 mm[Hg] | 8480-6 | S |
| 2008-04-13 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2008-04-13 | Heart rate | 72 /min | 8867-4 | S |
| 2008-04-13 | Respiratory rate | 16 /min | 9279-1 | S |
| 2008-04-13 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2008-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2008-05-18 | Body height | 182 cm | 8302-2 | S |
| 2008-05-18 | Body weight | 99.9 kg | 29463-7 | S |
| 2008-05-18 | Body mass index (BMI) [Ratio] | 30.2 kg/m2 | 39156-5 | S |
| 2008-05-18 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2008-05-18 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2008-05-18 | Heart rate | 74 /min | 8867-4 | S |
| 2008-05-18 | Respiratory rate | 16 /min | 9279-1 | S |
| 2008-05-18 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2008-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2008-09-14 | Body height | 182 cm | 8302-2 | S |
| 2008-09-14 | Body weight | 97.2 kg | 29463-7 | S |
| 2008-09-14 | Body mass index (BMI) [Ratio] | 29.3 kg/m2 | 39156-5 | S |
| 2008-09-14 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2008-09-14 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2008-09-14 | Heart rate | 72 /min | 8867-4 | S |
| 2008-09-14 | Respiratory rate | 16 /min | 9279-1 | S |
| 2008-09-14 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2008-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2008-07-13 | Body height | 182 cm | 8302-2 | S |
| 2008-07-13 | Body weight | 98.6 kg | 29463-7 | S |
| 2008-07-13 | Body mass index (BMI) [Ratio] | 29.8 kg/m2 | 39156-5 | S |
| 2008-07-13 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2008-07-13 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2008-07-13 | Heart rate | 72 /min | 8867-4 | S |
| 2008-07-13 | Respiratory rate | 16 /min | 9279-1 | S |
| 2008-07-13 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2008-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Former professional heavyweight boxer and Olympic champion; owns and runs a boxing gym in Philadelphia, where he trains young fighters most days
- S Grew up on a farm in South Carolina; moved to Philadelphia as a teenager and worked in a slaughterhouse
- S Money is tight; worries about the cost of medicines and appointments; prefers generics and 90-day supplies
- S Alcohol: one or two beers on some weekends (AUDIT-C 2); no other drug use
- S Tobacco: never
- S Activity: on his feet at the gym most of the day and holds pads for his fighters; no longer runs because of his knees
- S Strengths: discipline, pride in his work, the young fighters who rely on him, his faith, and a long habit of showing up
Functional status
- S Independent in all activities; walks without an aid; reads with his right eye
Mental status
- S Alert, direct and good-humored; oriented; fluent conversation with good recall of recent events; PHQ-9 score 4
Allergies and medications
Allergies
- S No known allergy
Medications
- S Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years
- S Lisinopril 20 mg oral tablet, one tablet daily; taken for years
- S Atorvastatin 40 mg oral tablet, one tablet daily
- S Amlodipine 5 mg oral tablet, one tablet daily
- S Amlodipine 10 mg oral tablet, one tablet daily
- S Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly
- S Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly
Procedures and immunizations
Procedures
- S Twelve-lead electrocardiogram
- S Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses
- S Liver transient elastography with controlled attenuation parameter
- S Liver ultrasound for hepatocellular carcinoma surveillance, baseline
- S Upper endoscopy to screen for varices
- S Dilated eye examination at the eye clinic
- S Liver ultrasound for hepatocellular carcinoma surveillance, six months
- S Advance care planning conversation, about 18 minutes
Immunizations
- S 2008-02-16: Tdap vaccine
- S 2008-03-02: Pneumococcal conjugate vaccine PCV20
- S 2008-03-02: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
- S 2008-03-02: Hepatitis A vaccine, adult, dose 1 of 2
- S 2008-04-13: Hepatitis B vaccine (HepB-CpG), dose 2 of 2
- S 2008-09-14: Hepatitis A vaccine, adult, dose 2 of 2
- S 2008-07-13: Recombinant zoster vaccine, dose 1 of 2
- S 2008-09-14: Recombinant zoster vaccine, dose 2 of 2
- S 2008-09-14: Influenza vaccine, inactivated, this season
- S 2008-09-14: COVID-19 vaccine, mRNA, this season
- S 2008-09-14: RSV vaccine, single dose
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1964: Broken left thumb in the 1964 Olympic final (CLM-0003)
- D 1964: Cataract in the left eye found at 20, with reduced vision in that eye through his boxing career (20/400 in that eye by 1975) (CLM-0004)
- D 1965 to 1976, and one bout in 1981: Professional heavyweight boxing career with many blows to the head, including a 1975 bout stopped when he could no longer see (CLM-0005, CLM-0006)
- D early 2000s: Diabetes and high blood pressure, reported publicly (CLM-0008)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| A1c below 7% within six to nine months, without low blood sugar | 2008-09-14 | completed | 8.4% to 6.8% at seven months; no low blood sugar |
| Blood pressure below 130/80 mmHg in the clinic and at home | 2008-09-14 | completed | 122/76 in the clinic; home average 124/78 |
| LDL cholesterol below 70 mg/dL | 2008-04-13 | completed | 132 to 68 mg/dL on atorvastatin |
| Weight loss of 7 to 10% for liver health within a year | 2008-09-14 | active | 104.0 to 97.2 kg (6.5%) at seven months |
| Liver cancer surveillance by ultrasound with AFP every six months, on time | 2008-09-14 | completed | Baseline and six-month ultrasounds with AFP on schedule; no focal lesion; AFP 4.2 and 4.0 ng/mL |
| No alcohol, to protect the liver | 2008-09-14 | completed | No alcohol since the two-week visit |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Diabetes: continue metformin, an A1c every three months until at goal and then every six months, diabetes self-management education, a vitamin B12 check on long-term metformin, and no medicine that causes low blood sugar | completed | GL-ADA-PHARM-2026, GL-CMID-2026 |
| Hepatology consultation for a high FIB-4 with mildly low platelets, with transient elastography and a liver ultrasound the same day | completed | GL-AASLD-MASLD-2023, GL-ADA-COMORB-2026 |
| Liver assessment: FIB-4 from the yearly liver tests, then transient elastography if FIB-4 is 1.3 or higher; hepatitis B, hepatitis C and HIV tests, iron studies, and an alcohol history | completed | GL-AASLD-MASLD-2023, GL-ADA-COMORB-2026, GL-CMID-2026 |
| Compensated cirrhosis: liver ultrasound with AFP every six months for hepatocellular carcinoma surveillance, upper endoscopy to screen for varices, hepatitis A and B and pneumococcal vaccines, no alcohol, no NSAIDs, acetaminophen no more than 2 g a day, and teaching on the warning signs of decompensation | completed | GL-AASLD-HCC-2023, GL-BAVENO-VII, GL-AASLD-MASLD-2023, GL-CDC-IMZ-2026 |
| Semaglutide once weekly, increased every four to eight weeks as tolerated, for its cardiovascular and kidney benefit, weight and steatotic liver disease; prior authorization and the manufacturer's assistance program handled by the clinic | completed | GL-ADA-PHARM-2026, GL-ADA-COMORB-2026, GL-AASLD-MASLD-2023 |
| Blood pressure: a validated home monitor with a large cuff, readings twice a day for a week, a goal below 130/80 mmHg, and less salt | completed | GL-AHA-HTN-2025, GL-CMID-2026 |
| Amlodipine added to lisinopril and increased to reach the goal, with ankle-swelling checks | completed | GL-AHA-HTN-2025, GL-ADA-CVD-2026 |
| Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks; a baseline ECG; aspirin for primary prevention not used because of bleeding risk | completed | GL-ADA-CVD-2026, GL-CMID-2026 |
| Kidneys: eGFR by the race-free CKD-EPI 2003 equation and urine albumin-to-creatinine ratio at least yearly, and potassium and creatinine on lisinopril | completed | GL-ADA-CKD-2026, GL-CMID-2026 |
| Eyes and feet: a dilated eye examination at the eye clinic, a comprehensive foot examination yearly, daily foot checks and callus care | completed | GL-ADA-RETFOOT-2026 |
| Brain health: a documented cognitive screen at the preventive visit, blood pressure and glucose control, sleep, hearing and mood checks, and an honest conversation that chronic traumatic encephalopathy cannot be diagnosed during life | completed | GL-NINDS-TES-2021, GL-CMID-2026 |
| Cost and access: low-cost generics, 90-day supplies, and help with coverage for any brand-name medicine | completed | GL-ADA-POP-2026 |
Planned encounters
- 2008-02-16 — Establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxer (ENC-001)
- 2008-03-02 — Two-week review of home blood pressure readings, with liver elastography, a liver ultrasound and the hepatology consultation (ENC-002)
- 2008-04-13 — Eight-week review: blood pressure, lipids, kidney function, semaglutide, the endoscopy result and vaccines (ENC-003)
- 2008-05-18 — Three-month review: A1c, blood pressure, weight, semaglutide dose and the eye examination (ENC-004)
- 2008-07-13 — Periodic adult preventive visit (ENC-006)
- 2008-09-14 — Seven-month review: six-month liver cancer surveillance ultrasound and AFP, A1c, kidney function, urine albumin and vaccines (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Hepatology referral
- Hepatology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Hepatology referral (XML)
- Hepatology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Sielski M. Joe Frazier biography (ESPN Classic) | ESPN | biography |
| SRC-0002 | Diskin B. Smokin' Joe had vicious left hook (ESPN Classic) | ESPN | other |
| SRC-0003 | Boxing legend Joe Frazier dies | ESPN.com news services | other |
| SRC-0004 | Gelston D, Dahlberg T. Philadelphia boxing legend Joe Frazier dies (Associated Press) | The Philadelphia Inquirer | other |
| SRC-0005 | Joe Frazier dead at 67 (Associated Press) | CBS Los Angeles | other |
| SRC-0006 | Ex-champ Frazier dies of liver cancer (Associated Press) | The Vindicator | other |
| SRC-0007 | Cancer catches Joe Frazier | The Irish Times | other |
| SRC-0008 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the FIB-4 to elastography pathway, the diagnosis of compensated cirrhosis from a liver stiffness of 17.6 kPa with platelets of 138 and ultrasound findings, the endoscopy rather than a beta-blocker, six-monthly ultrasound with AFP, semaglutide with metformin, the eGFR without a race term, amlodipine with lisinopril, aspirin not used, and the cognitive screen without a CTE diagnosis. |
| provenance review | not_started | Sources: an ESPN Classic biography and an ESPN Classic article written during his life, and obituaries from ESPN, the Associated Press (The Philadelphia Inquirer, CBS Los Angeles, The Vindicator) and The Irish Times. A posthumous magazine profile was not used. |
| safe messaging review | not_started | Recent-death rule: only what was reported publicly during his life or in obituaries and statements by his manager and family. No sick visit. No mental health or substance claim is made. The liver disease, cognitive screen and every clinical finding are synthetic. No living relative is named, and his rival is not named. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.